Localized Delivery of Antimicrobial Agents Template

Localized delivery of antimicrobial agents - per tooth.

RMH: Medical history reviewed/updates

Tooth: #Tooth number(s)
Site: Site/tooth area
Indication: Indication/diagnosis
Persistent pocket despite SRP.
Localized infection.

Localized antimicrobial support: Persistent pocket/site after SRP, probing depth, BOP/suppuration
Medication details: Agent, dose/amount, lot/expiration if applicable
Re-evaluation plan: Follow-up interval and criteria

Procedure:
Area isolated.
Site dried.
Antimicrobial agent placed: Antimicrobial agent placed
Placement confirmed.

Patient Instructions:
Do not floss treated area for 10 days.
Avoid chewing hard or sticky foods on treated area.
May experience mild discomfort.

Complications: None or describe.
Patient tolerance: Tolerance/response.

NV: Next visit

Documentation requirements

D4381 is one of the most frequently audited periodontal adjunct codes. The chart note has to make three things obvious: that the patient has periodontitis, that mechanical therapy was performed first and didn't fully resolve the site, and that the specific tooth being treated meets the pocket/BOP threshold today.

• Periodontal diagnosis (stage and grade) — explicit AAP staging (Stage II / III / IV, Grade A / B / C) or the legacy "moderate / severe periodontitis" language, with the date of diagnosis. Generalized gingivitis without periodontitis does not qualify.
• Prior therapy reference — date and code of the SRP (D4341/D4342) or perio maintenance (D4910) that preceded today's visit, and the elapsed interval. AAP and most carriers want SRP first, then re-evaluation typically at 4–8 weeks, then D4381 only at sites that haven't responded.
• Tooth number(s) treated — list every tooth that received placement. D4381 is per tooth; the claim line must match the chart.
• Site within the tooth — mesial / distal / buccal / lingual. Some carriers want the specific site, not just the tooth.
• Probing depth at the treated site, today — actual mm reading. "Generalized 5+ mm" is not site-specific enough. Carriers commonly require ≥5 mm; some accept 4 mm post-surgically.
• BOP and/or suppuration at the site, today. Pocket depth alone is rarely sufficient; an inactive 5 mm pocket without BOP is harder to defend.
• Why this site is refractory — one line connecting today's finding to the prior therapy ("PD #19 DL was 6 mm with BOP at SRP on 2026-01-12; persists at 5 mm with BOP today, 10 weeks post-SRP").
• Agent, manufacturer, and dose — "Arestin (OraPharma) 1 mg minocycline microspheres," "Atridox 10% doxycycline gel," or "PerioChip 2.5 mg chlorhexidine." Lot number and expiration where available; some boards require it for any in-office drug placement.
• Procedure detail — site isolated, dried, agent delivered subgingivally, placement confirmed. For Atridox, note the gel set/cured. For PerioChip, note the chip seated below the gingival margin.
• Post-op instructions given — no flossing the treated site for 10 days, no sticky/hard foods at the site, expected mild discomfort, when to call. AAP / OraPharma post-op instructions are the standard.
• Re-evaluation plan — interval (typically 4–6 weeks) and the criterion that defines success (PD reduction, resolution of BOP). This is the documentation that keeps a future D0171 / D4910 / repeat-D4381 claim defensible.
• Operator and supervising provider initials — many states allow RDH placement of locally applied antimicrobials under direct/indirect supervision; the supervising dentist's name should still appear in the note.
• Medical history review — at minimum a "no changes / changes noted" line. Tetracycline-class allergies are a contraindication for Arestin/Atridox; document the screen.

A note that reads like the auto-template (defaults left in place — "persistent pocket despite SRP, localized infection") with no actual probing depth, no BOP/sup status, and no SRP date is the textbook audit target. Replace every bracket with patient-specific data.

Common denial reasons

The most frequent reasons D4381 is denied, downgraded, or recouped:

• No prior SRP documented — by far the most common audit finding. The carrier sees D4381 with no D4341/D4342 in the patient's claim history (or no SRP date in the narrative) and denies for missing precedent. Supplying the SRP date and code in the narrative line is the cheapest fix.
• Pocket depth not stated, or stated as <5 mm — generic "deep pockets" or "generalized 5+ mm" instead of a per-tooth probing depth. Reviewers want a number on the treated site, today.
• No BOP or suppuration at the site — a 5 mm pocket without active inflammation is the weakest case for medical necessity. Plans like Aetna and Cigna explicitly cite BOP as a coverage criterion.
• Same-DOS SRP conflict — Aetna, Delta, and several BCBS plans bundle D4381 into D4341/D4342 when both are billed on the same date, because there has been no opportunity to evaluate SRP response.
• Diagnosis mismatch — D4381 billed for a patient whose claim history shows only D1110 prophy / gingivitis treatment (no periodontitis). Without an active perio Dx, the code fails the medical-necessity gate.
• Quadrant- or arch-wide placement — billing 6, 8, or 12 D4381 units in a single visit is the classic utilization-outlier pattern flagged in payer audits and state OIG reports. Carriers will pay a few teeth and recoup the rest, or open a chart audit.
• No re-evaluation interval between SRP and D4381 — same-visit or next-visit Arestin without a documented 4–8 week re-evaluation gives the carrier grounds to deny as "premature."
• Generalized gingivitis — D4381 used on patients without periodontitis. The correct code for inflammation in the absence of periodontitis is D4346 (scaling in the presence of generalized moderate/severe gingival inflammation), not D4381.
• Peri-implant placement — billing D4381 on an implant. Not a covered indication; reroute to implant maintenance coding.
• Refilled "Arestin" line in the chart with no actual placement detail — auto-template language ("persistent pocket despite SRP, localized infection") with no PD reading, no BOP, no agent details reads as fabricated to a reviewer and is a documented downgrade trigger.
• Tetracycline allergy ignored — billing Arestin/Atridox on a patient with a documented tetracycline allergy is both a clinical and a documentation problem.
• Frequency violation — re-billing D4381 on the same tooth within the carrier's 90- or 180-day lookback without a new re-evaluation showing residual PD ≥5 mm + BOP.

Related templates